PUBLIKATIONSLISTE. Rupert Bartsch Impact Factor (IF) 185,607. Total Cites (September 2011): 381

Transkript

1 PUBLIKATIONSLISTE Rupert Bartsch 2010 Impact Factor (IF) 185,607 Total Cites (September 2011): 381 ORIGINALARBEITEN IF 174,875 Erstautor / Corresponding Author IF 67,879 Top IF 45, BARTSCH R, FROMM S, RUDAS M, WENZEL C, HARBAUER S, ROESSLER K, KITZ K, STEGER GG, WEITMANN HD, POETTER R, ZIELINSKI CC, DIECKMANN K. Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer. Radiother Oncol 2006;80: IF 4, BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, BACHLEITNER- HOFFMANN T, LOCKER GJ, RUDAS M, MADER R, ZIELINSKI CC, STEGER GG. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast Cancer Res Treat 2007;102: IF 4, BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, MADER RM, GNANT M, JAKESZ R, RUDAS M, ZIELINSKI CC, STEGER GG. Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin Cancer Res 2007;13: IF 7, BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, RUDAS M, MADER RM, GNANT M, ZIELINSKI CC; STEGER GG. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25: IF 18, BARTSCH R, MLINERITSCH B, GNANT M, NIERNBERGER T, PLUSCHNIG U, GREIL R, WENZEL C, SEVELDA P, THALER J, RUDAS M, POBER M, ZIELINSKI CC, STEGER GG, on behalf of the Austrian Fulvestrant Registry. The Austrian fulvestrant registry - results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Breast Cancer Res Treat 2009;115: IF 4, BARTSCH R, BERGHOFF A, PLUSCHNIG U, BAGO-HORVATH Z, DUBSKY P, ROTTENFUSSER A, DEVRIES C, RUDAS M, FITZAL F, DIECKMANN K, GNANT M, MADER RM, ZISLINSKI C, STEGER GG. Impact of Anti-Her2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. British Journal of Cancer 2011;[Epub ahead of print]. IF 4,831 Rupert Bartsch 1

2 Sonstige IF 22, BARTSCH R, WENZEL C, SEVELDA U, HUSSIAN D, PLUSCHNIG U, LOCKER GJ, MADER R, ZIELINSKI CC, STEGER GG. Darbepoetin alfa as treatment for anaemia in patients receiving chemotherapy: a single-centre experience. Anticancer Drugs 2005;16: IF 2, BARTSCH R, WENZEL C, PLUSCHNIG U, HUSSIAN D, SEVELDA U, LOCKER GJ, MADER R, ZIELINSKI CC, STEGER GG. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemoth Pharmacol 2006;57: IF 2, BARTSCH R, WEITMANN HD, PENNWIESER W, WENZEL C, MUSCHITZ S, BALDASS M, ROESSLER K, HASSLER M, MAROSI C, POETTER R, DIECKMANN K. Retrospective analysis of re-irradiation in malignant glioma: a single-center experience. Wien Klin Wochenschr 2005;117: IF 0, BARTSCH R, WENZEL C, HUSSIAN D, PLUSCHNIG U, SEVELDA U, KOESTLER W, ALTORJAI G, LOCKER GJ, MADER R, ZIELINSKI CC, STEGER GG. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 2006;6:63. IF 3, BARTSCH R, WENZEL C, PLUSCHNIG U, HUSSIAN D, SEVELDA U, LOCKER GJ, MADER R, ZIELINSKI CC, STEGER GG. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment BMC Cancer 2006;6:81. IF 3, BARTSCH R, WOEHRER S, RADERER M, HEJNA M. Serum Interleukin-6 levels in patients with stage I MALT-lymphoma compared to gastric and pancreatic cancer. Anticancer Res 2006;26: IF 1, BARTSCH R, ROTTENFUSSER A, WENZEL C, DIECKMANN K, PLUSCHNIG U, ALTORJAI G, RUDAS M, MADER RM, POETTER R, ZIELINSKI CC, STEGER GG. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neuro Oncol 2007;85: IF 2, BARTSCH R, STEGER GG, FORSTNER B, WENZEL C, PLUSCHNIG U, RIZOVSKI B, ZIELINSKI CC, MADER RM. Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel. BMC Clin Pharmacol 2007;7:7. IF n.a. 9. BARTSCH R, WENZEL C, GAMPENRIEDER S, PLUSCHNIG U, ALTORJAI G, RUADS M, MADER RM, DUBSKY P, ROTTENFUSSER A, GNANT M, ZIELINSKI CC, STEGER GG. Rupert Bartsch 2

3 Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemoth Pharmacol 2008;62: IF 2, BARTSCH R, DE VRIES C, PLUSCHNIG U, DUBSKY P, HORVATH Z, GAMPENRIEDER SP, RUDAS M, MADER RM, ROTTENFUSSER A, WILTSCKE C, GNANT M, ZIELINSKI CC, STEGER GG. Predicting time to progression and response to second-line trastuzumab-based therapy in Her2-positive advanced breast cancer. BMC Cancer 2009;9:367. IF 3,153 Coautor IF 103,483 Top IF 88, WOEHRER S, STREUBEL B, BARTSCH R, CHOTT A, RADERER M. Monoclonal immunoglobulin production is a frequent event in patients with MALT Lymphoma. Clin Cancer Res 2004;10: IF 7, RADERER M, WOEHRER S, BARTSCH R, PRAGR G, DRACH J, HEJNA M, GAIGER A, TURETSCHEK K, JAEGER U, STREUBEL B, ZIELINSKI CC. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23: IF 18, STEGER GG, BARTSCH R, WENZEL C, PLUSCHNIG U, LOCKER GJ, HUSSIAN D, SEVELDA U, ZIELINSKI CC. Fulvestrant ( Faslodex ) in pre-treated patients with advanced breast cancer: A single-centre experience. Eur J Cancer 2005;41: IF 4, WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, ALTORJAI G, ZIELINSKI CC, LANG A, HAID A, JAKESZ R, GNANT M, STEGER GG. Invasiv ductal carcinoma and lobular of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat 2007;104: IF 4, DUBSKY P, SEVELDA P, JAKESZ R, HAUSMANINGER H, SAMONIGG H, SEIFERT M, DENISON U, MLINERITSCH B, STEGER G, KWASNY W, STÖGER J, BARTSCH R, STIERER M, TAUCHER S, FRIDRIK M, SCHIPPINGER W, GREIL R, PÖTTER R, GNANT M for the Austrian Breast and Colorectal Cancer Study Group. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5- fluorouracil chemotherapy. Clin Cancer Res 2008;14: IF 7, TOMOVA A, BARTSCH R, BRODOWICZ T, TZEKOVA V, TIMCHEVA C, WILTSCHKE C, GERGES DA, PAWLEGA J, SPANIK S, INBAR M, ZIELINSKI CC. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable Rupert Bartsch 3

4 breast cancer patients: A prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). Breast Cancer Res Treat 2010; IF 4, WIEDERMANN U, WILTSCHKE C, JASINSKA J, KUNDI M, ZURBRIGGEN R, GARNER-SPITZER E, BARTSCH R, STEGER G, PEHAMBERGER H, SCHEINER O, ZIELINSKI CC. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat 2010;119: IF 4, MICHLMAYR A, BACHLEITNER-HOFMANN T, BAUMANN S, MARCHETTI- DESCHMANN M, RECH-WEICHSELBRAUN I, BURGHUBER C, PLUSCHNIG U, BARTSCH R, GRAF A, GREIL R, STEGER G, GNANT M, BERGMANN M, OEHLER R. Modulation of plasma complement by the initial dose of epirubicin/docetaxel combination therapy in breast cancer and its predictive value. Br J Cancer 2010;103: IF 4, FITZAL F, RIEDL O, MITTLBÖCK M, DUBSKY P, STEGER G, BARTSCH R, JAKESZ R, GNANT M. Oncologic safety of breast conserving surgery after tumor downsizing by neoadjuvant therapy: A retrospective single centre cohort study. Breast Cancer Res Treat 2011;127: IF 4, FITZAL F, MITTLBOECK M, STEGER G, BARTSCH R, RUDAS M, DUBKSY P, RIEDL O, JAKESZ R, GNANT M. Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type Breast Cancer Patients: Ann Surg Oncol 2011;[Epub ahead of print] IF 4, DUBSKY P, JAKESZ R, MLINERITSCH B, PÖSTLBERGER S, SAMONIGG H, KWASNY W, TAUSCH C, STÖGER H, HAIDER K, FITZAL F, SINGER CF, STIERER M, SEVELDA P, LUSCHIN-EBENGREUTH G, TAUCHER S, RUDAS M, BARTSCH R, STEGER G, GREIL R, FILIPCIC L, GNANT M, on behalf of the ABCSG. Tamoxifen and anastrozole as a sequencing strategy: A randomized controlled trial in 3714 postmenopausal patients with endocrine responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2011;[in press] IF 18,970 Sonstige IF 21, WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, ZIELINSKI CC, STEGER GG. Capecitabine-monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Anticancer Drugs 2003;14: IF 2, STEGER GG, WENZEL C, BARTSCH R, RUDAS M, GNANT M, ZIELINSKI CC, JAKESZ R. Rupert Bartsch 4

5 Preliminary results of a pilot-trial with trastuzumab + weekly epidoxorubicin/docetaxel in the neoadjuvant treatment of primary, operable breast cancer Breast 2003;12(Suppl.1):S IF 2, WENZEL C, HUSSIAN D, BARTSCH R, PLUSCHNIG U, LOCKER GJ, RUDAS M, GNANT M, JAKESZ R, ZIELINSKI CC, STEGER GG. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 2004;12: IF 2, WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHING U, LOCKER GJ, SEVELDA U, ZIELINSKI CC, STEGER GG. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome. Support Care Cancer 2004;12: IF 2, WENZEL C, LOCKER GJ, BARTSCH R, PLUSCHNIG U, HUSSIAN D, ZIELINSKI CC, STEGER GG. Preoperative second-line chemotherapy induces objective responses in primary breast cancer. Wien Klin Wochenschr 2005;117: IF 0, WOEHRER S, BARTSCH R, HAJNA M, DRACH J, RADERER M. Routine application of the proton pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy Scand J Gastroenterol 2005;40: IF 1, WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, SEVELDA U, ZIELINSKI CC, STEGER GG. Preoperative therapy with epidoxorubicin/docetaxel/capecitabine plus pegfilgrastim (TEX + P) in primary breast cancer: a pilot study. Anticancer Drugs 2005;16: IF 2, FROMM S, BARTSCH R, RUDAS M, WENZEL C, DE VRIES A, STEGER GG, ZIELINSKI CC, POETTER R, DIECKMANN K. Time to development of brain metastases in breast cancer: a retrospective analysis of risk factors. Breast 2008;17: IF 2, FROMM-HAIDENBERGER S, POHL G, WIDDER J, KREN G, FITZAL F, BARTSCH R, DE VRIES J, ZIELINSKI C, PÖTTER R. Vienna International Summer School on Experimental and Clinical Oncology for medical students: an Austria cancer education project. J Cancer Educ 2010;25:51-4. IF 0, KIERNER KA, GARTNER V, BARTSCH R, HLADSCHIK-KERNER B, GRUBER A, HASSLER M, WATZKE HH. Attitudes towards palliative care in primary metastatic cancer: a survey among oncologists. Wien Klin Wochenschr 2010;122:45-9. IF 0, GAMPENRIEDER SP, BARTSCH R, PLUSCHNIG U, MATZNELLER P, SCHEUER R, DUBSKY P, GNANT M, ZIELINSKI CC, STEGER GG. Rupert Bartsch 5

6 Capecitabine and vinorelbine as an all-oral chemotherapy in Her2-negative locally advanced and metastatic breast cancer. Breast Care 2010;5: IF 0, FIEGL M, MLINERITSCH B, HUBALEK M, BARTSCH R, PLUSCHNIG U, STEGER GG. Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial. BMC Cancer 2011;11:373. IF 3,153 SONSTIGE PUBLIKATIONEN IF 10, BARTSCH R. Comment on the letter to the editor Hormone receptor status as an independent variable affecting the survival of advanced breast cancer patients with brain metastases (Hakan Harputluoglu et al.). Letter to the editor Radiother Oncol 2007;2:375. IF 4, BARTSCH R, WENZEL C, ZIELINSKI CC, STEGER GG. Her-2 positive breast cancer: hope beyond trastuzumab. Bio Drugs 2007;21: IF 4, BARTSCH R, WENZEL C, STEGER GG. Trastuzumab in the management of early and advanced stage breast cancer. Biologics 2007;1:5. 4. BARTSCH R, STEGER GG. Adjuvant chemotherapy in breast cancer. Magazine of European Medical Oncology 2008;1:91-8. IF n.a. IF n.a. 5. BARTSCH R, STEGER GG. The role of supportive therapy in the era of modern adjuvant treatment current and future tools. Breast Care 2009;4: IF 0, BARTSCH R, STEGER GG. Role of denosumab in breast cancer. Expert Opin Biol Ther 2009;9: BARTSCH R, STEGER GG. Metastatic breast cancer: review on chemotherapy. (German) Senologie 2009;6: IF n.a. IF n.a. 8. BARTSCH R, ZIEBERMAYR R, ZIELINSKI CC, STEGER GG. Rupert Bartsch 6

7 Triple negative breast cancer. Wien Med Wochenschr 2010;160: IF n.a. 9. BARTSCH R, STEGER GG, ZIELINSKI CC, ZIEBERMAYR R. Breast Cancer: Rank-ligand inhibition. Breast Care 2010;5: IF 0, BARTSCH R, ZIEBERMAYR R. ASCO 2010: update on metastatic breast cancer. Magazine of European Medical Oncology 2010;3: IF n.a. 11. STEGER GG, BARTSCH R. Denosumab for the treatment of bone metastases in breast cancer: Evidence and opinion. Ther Adv Med Oncol 2011;3: IF n.a. 12. BARTSCH R, STEGER GG. Mammakarzinom (German) Wien Klin Wochenschr Educational 2011;[in press]. IF 0, BARTSCH R, DUBSKY PC, LOIBL S, STEGER GG. Opinions on the ASCO 2011 Annual Meeting Expert Panel Breast Care 2011;6: IF 0, STEGER GG, BARTSCH R. Trends and novel approaches in neoadjuvant treatment. Breast Care 2011;[in press]. IF 0, BARTSCH R, ZIELINSKI CC. Adjuvant systemic therapy for early breast cancer Emirates Journal of Medical Sciences;[in press]. IF n.a. PUBLIKATIONEN (IM PEER REVIEW VERFAHREN) Erstautor / Corresponding Author 1. BERGHOFF A, BAGO-HORVATH Z, DUBSKY P, RUDAS M, PLUSCHNIG U, WILTSCHKE C, GNANT M, STEGER GG, ZIELINSKI CC, BARTSCH R. Impact of her-2 targeted therapy on overall survival in patients with her-2 positive metastatic breast cancer. Submitted to Breast Journal Rupert Bartsch 7

8 2. BARTSCH R, BAGO-HORVATH Z, PLUSCHNIG U, DEVRIES C, BERGHOFF A, DUBSKY P, RUDAS M, MADER RM, ROTTENFUSSER A, FITZAL F, GNANT M, ZIELINSKI CC, STEGER GG. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Submitted to European Journal of Cancer 3. BERGHOFF A, BAGO-HORVATH Z, DE VRIES C, DUBSKY P, PLUSCHNIG U, RUDAS M, ROTTENFUSSER A, KNAUER M, EITER H, FITZAL F, DIECKMANN K, MADER R, GNANT M, ZIELINSKI CC, STEGER GG, PREUSSER M, BARTSCH R. Brain metastases free survival differs between breast cancer subtypes. Submitted to British Journal of Cancer Coautor 1. PLUSCHNIG U, HASLIK W, BAYER G, SOLEIMAN A, BARTSCH R, LAMM W, STEGER GG, ZIELINSKI CC, MADER RM. Extravasation of cytotoxic agents: novel aspects of diagnosis and clinical management - the Vienna experience Submitted to Lancet 2. ARNOLD T, MICHLMAYR A, BAUMANN A, BURGHUBER C, PLUSCHNIG U, BARTSCH R, STEGER G, GNANT M, BERGMANN M, BACHLEITNER-HOFMANN T, OEHLER R. Increase in plasma HMGB-1 after initial dose of epirubicin/docetaxel in breast cancer is associated with response to therapy. Submitted to BMC Cancer BUCHBEITRÄGE 1. BARTSCH R, STEGER G. Denosumab das Molekül: Erster klinischer Einsatz (German). In: Gnant M, Hadji P (Eds.). Osteo-Onkologie RANKL-Inhibition beim Mammakarzinom, pp Uni-Med Verlag BARTSCH R, STEGER G. Mammakarzinom (German). In: Marian B (Ed.). Krankheit, Krankheitsursachen und -bilder, pp Facultas. wuv BARTSCH R, STEGER GG. Trastuzumab as adjuvant treatment for early stage Her2-positive breast cancer. In: Sibilia M, Zielinski CC, Bartsch R, Grunt T (Eds.). Milestones in Drug Therapy: Drugs for HER-2-positive Breast Cancer, pp Springer Basel ABSTRACTS Erstautor / Corresponding Author Rupert Bartsch 8

9 1. BARTSCH R, WENZEL C, PLUSCHNIG U, HUSSIAN D, ZIELINSKI CC, STEGER GG. Preoperative second-line chemotherapy induces objective responses in primary breast cancer. ECCO 12, September 2003, Kopenhagen, Dänemark - ABSTRACT 2. BARTSCH R, HUSSIAN D, WENZEL C, PLUSCHNIG U, LOCKER G, MADER R, ZIELINSKI CC, STEGER GG. Darbepoetin alfa in the treatment of anaemia in patients receiving chemotherapy. 20. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO- ASSO), September 2003, Wien, Österreich - VORTRAG 3. BARTSCH R, PLUSCHNIG U, WENZEL C, HUSSIAN D, LOCKER GJ, MADER R, ZIELINSKI CC, STEGER GG. Oral Vinorelbine in the treatment of advanced breast cancer Annual Meeting of the American Society of Clinical Oncology, Juni 2004, New Orleans, USA - POSTER 4. BARTSCH R, STEGER GG, WENZEL C, PLUSCHNIG U, HUSSIAN D, SEVELDA U, MADER R, ZIELINSKI CC. Prognostic value of tumour markers CA 15-3 and CEA during fulvestrant treatment Annual Meeting of the American Society of Clinical Oncology, Mai 2005, Orlando, USA - ABSTRACT 5. BARTSCH R, WENZEL C, HUSSIAN D, KOESTLER W, PLUSCHNIG U, SEVELDA U, LOCKER G, MADER R, ZIELINSKI CC, STEGER GG. Do HER2 positive patients profit from continued trastuzumab treatment beyond disease progression? A single centre experience. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2005, Oktober 2005, Hannover, Deutschland - POSTER 6. BARTSCH R, WENZEL C, HUSSIAN D, SEVELDA U, PLUSCHNIG U, LOCKER G, MADER R, ZIELINSKI CC, STEGER GG. Results from an observational trial of darbepoetin alfa as treatment for anaemia in patients on chemotherapy. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2005, Oktober 2005, Hannover, Deutschland - POSTER 7. BARTSCH R, WENZEL C, PLUSCHNIG U, HUSSIAN D, SEVELDA U, MADER R, ZIELINSKI CC, STEGER GG. Value of tumour markers CA 15-3 and CEA in predicting response and progression during fulvestrant treatment. ECCO 13, Oktober 2005, Paris, Frankreich - POSTER 8. BARTSCH R, WENZEL C, HUSSIAN D, KOESTLER W, PLUSCHNIG U, SEVELDA U, LOCKER G, MADER R, ZIELINSKI CC, STEGER GG. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. ECCO 13, Oktober 2005, Paris, Frankreich - ABSTRACT 9. BARTSCH R, MUSCHITZ S, RUDAS M, WENZEL C, HARBAUER S, ROESSLER K, STEGER GG, POETTER R, DIECKMANN K. Boost irradiation and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer. Jahrestagung der österreichischen Gesellschaft für Radioonkologie 2005, Dezember 2005, Salzburg, Österreich - VORTRAG Rupert Bartsch 9

10 10. BARTSCH R, MUSCHITZ S, WENZEL C, ROESSLER K, DIECKMANN K, WEITMANN HD, POETTER R, ZIELINSKI CC, STEGER GG. Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer Annual Meeting of the American Society of Clinical Oncology, Juni 2006, Atlanta, USA - ABSTRACT 11. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, MADER R, GNANT M, JAKESZ R, RUDAS M, ZIELINSKI C, STEGER G. Das Ansprechen auf Fulvestrant ist abhängig von der Proliferationsrate, jedoch nicht von p53, Grading, Progesteronrezeptor, und Her2-Status. Jahrestagung der österreichischen Gesellschaft für Senologie, September 2006, Salzburg, Österreich - POSTER 12. BARTSCH R, WENZEL C, PLUSCHNIG U, ALTORJAI G, BACHLEITNER- HOFMANN T, LOCKER G, RUDAS M, MADER R, ZIELINSKI C, STEGER G. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2006, Oktober 2006, Leipzig, Deutschland - POSTER 13. BARTSCH R, WENZEL C, ALTORJAI G, LUSCHNIG U, MADER R, GNANT M, JAKESZ R, ZIELISNKI CC, STEGER GG. High proliferation rate but not p53, grading, progesterone receptor status, and Her2 status predicts response to fulvestrant. 29 th Annual San Antonia Breast Cancer Symposium, Dezember 2006, San Antonio, Texas, USA - POSTER 14. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, LOCKER GJ, RUDAS M, MADER RM, ZIELINSKI CC, STEGER GG. Trastuzumab (T) plus capecitabine (C) in heavily pretreated patients (pts) with advanced breast cancer (ABC) Annual Meeting of the American Society of Clinical Oncology, Juni 2007, Chicago, USA - POSTER 15. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, LOCKER GJ, RUDAS M, MADER RM, ZIELINSKI CC, STEGER GG. Combination of capecitabine and trastuzumab is effective in heavily pretreated patients with metastatic breast cancer ASCO Breast Cancer Symposium, September 2007, San Francisco, USA - POSTER 16. BARTSCH R, WENZEL C, PLUSCHNIG U, ALTORJAI G, ZIELINSKI CC, STEGER GG. Trastuzumab-treatment beyond progression the Vienna experience Joint Meeting of the Slovenian and Austrian Society of Senology, September 2007, Graz, Österreich - VORTRAG (invited) 17. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, LOCKER GJ, RUDAS M, MADER RM, ZIELINSKI CC, STEGER GG. Capecitabine plus trastuzumab: An effective salvage regimen in heavily pretreated patients with metastatic breast cancer. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2007, Oktober 2007, Basel, Schweiz - VORTRAG Rupert Bartsch 10

11 18. BARTSCH R, MLINERITSCH B, GNANT M, NIERNBERGER T, PLUSCHNIG U, GREIL R, POBER M, SEVELDA P, THALER J, STEGER GG. The Austrian fulvestrant registry results from a prospective observation of fulvestrant in postmenopausal patients Annual Meeting of the American Society of Clinical Oncology, Juni 2008, Chicago, USA - POSTER 19. BARTSCH R, WENZEL C, PULSCHNIG U, ALTORJAI G, DUBSKY P, SCHEUER R, ROTTENFUSSER A, GNANT M, ZIELINSKI CC, STEGER GG. Combination of trastuzumab and gemcitabine as salvage therapy in heavily pretreated patients with metastatic breast cancer. The 6 th European Breast Cancer Conference (EBCC 6), April 2008, Berlin, Deutschland - POSTER 20. BARTSCH R, WENZEL C, PULSCHNIG U, ALTORJAI G, DUBSKY P, SCHEUER R, ROTTENFUSSER A, GNANT M, ZIELINSKI CC, STEGER GG. Trastuzumab and gemcitabine in heavily pre-treated patents with metastatic breast cancer Frühjahrstagung 2008 der ÖGHO, April 2008, Innsbruck, Österreich - VORTRAG 21. BARTSCH R, WENZEL C, GAMPENRIEDER SP, PLUSCHNIG U, BLAHA P, ALTORJAI G, GNANT M, RUDAS M, ROTTENFUSSER A, MADER RM, ZIELINSKI CC, STEGER GG. Oral vinorelbine in metastatic breast cancer the Vienna experience Jahrestagung der European Society of Medical Oncology, September 2008, Stockholm, Schweden - POSTER 22. BARTSCH R, MLINERITSCH B, GNANT M, NIERNBERGER T, PLUSCHNIG U, GREIL R, POBER M, THALER J, ZIELINSKI CC, STEGER GG, on behalf of the Austrian Fulvestrant Registry. The Austrian Fulvestrant Registry: results from a prospective observation of fulvestrant in postmenopausal patients ASCO Breast Cancer Symposium, September 2008, Washington, USA - POSTER 23. BARTSCH R, KNAUER M, ROTTENFUSSER A, WENZEL C, DIECKMANN K, EITER H, PLUSCHNIG U, DE VRIES A, ZIELINSKI CC, STEGER GG. Analysis of risk factors associated with early development of brain metastases in patients with metastatic breast cancer. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2008, Oktober 2008, Wien, Österreich - POSTER 24. BARTSCH R, MLINERITSCH B, GNANT M, NIERNBERGER T, PLUSCHNIG U, GREIL R, POBER M, THALER J, ZIELINSKI CC, STEGER GG, on behalf of the Austrian Fulvestrant Registry. A prospective observation of fulvestrant in postmenopausal patients: the Austrian Fulvestrant Registry. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2008, Oktober 2008, Wien, Österreich - POSTER 25. BARTSCH R, DUBSKY P, JAKESZ R, STEGER GG, GNANT M. Bisphosphonates in early breast cancer: Successes and challenges towards individualized therapy. 14 th Days of Prof. Vladimira Staska Meeting, März 2009, Prag, Tschechien - VORTRAG (invited) 26. BARTSCH R, ZIELINSKI CC, on behalf of the Consensus Participants and CECOG. Third consensus on the medical treatment of metastatic breast cancer. Rupert Bartsch 11

12 2 nd Interconference Breast Cancer Meeting, April 2009, Sarajevo, Bosnien-Herzegowina - VORTRAG (invited) 27. BARTSCH R, WENZEL C, PLUSCHNIG U, DUBSKY P, GAMPENRIEDER SP, RUDAS M, MADER R, GNANT M, ZIELINSKI CC, STEGER GG. Predicting response to second-line trastuzumab-based therapy in patients (pts) with her2-positive advanced breast cancer (ABC) Annual Meeting of the American Society of Clinical Oncology, Juni 2009, Orlando, USA - POSTER 28. BARTSCH R, DE VRIES C, PLUSCHNIG U, DUBSKY P, HORVATH S, RUDAS M, MADER RM, GNANT M, ZIELISNKI CC, STEGER GG. Analysis of factors predicting response to second-line trastuzumab-based therapy in patients (pts) with Her2-positive advanced breast cancer (ABC). ECCO 15, September 2009, Berlin, Deutschland - POSTER 29. BARTSCH R, DE VRIES C, PLUSCHNIG U, DUBKSY P, HORVATH S, RUDAS M, MADER R, GNANT M, ZIELINSKI C, STEGER G. Predicting for benefit from trastuzumab in multiple lines. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2009, Oktober 2009, Mannheim und Heidelberg, Deutschland - VORTRAG 30. BARTSCH R, DE VRIES C, KNAUER M, PLUSCHNIG U, ROTTENFUSSER A, BAGO-HORVATH Z, DIECKMANN K, EITER H, RUDAS M, DE VRIES A, ZIELINSKI CC, STEGER GG. Prädiktive Faktoren zum frühzeitigen Auftreten von Hirnmetastasen. Jahrestagung der österreichischen Gesellschaft für Senologie, September 2009, Velden, Österreich - VORTRAG 31. BARTSCH R. Targeted therapies: Enthusiastic interest, critical disappointment, renewed appreciation. 26. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO- ASSO), Oktober 2009, St. Wolfgang, Österreich - VORTRAG (invited) 32. BASRTCH R, KNAUER M, DE VRIES C, PLUSCHNIG U, BAGO-HORVATH Z, GNANT M, DIECKMANN C, ZIELINSKI CC, DE VRIES A, STEGER GG. Analysis of risk factors associated with early development of brain metastases in breast cancer. The 7 th European Breast Cancer Conference (EBCC 7), März 2010, Barcelona, Spanien - POSTER 33. BARTSCH R, DE VRIES C, FOEDERMAYR M, PLUSCHNIG U, HUBER M, BAGO- HORVATH Z, GIRSCHIKOFSKY M, STEGER GG, DUBSKY P, GNANT M, ZIELINSKI CC, ZIEBERMAYR R. Metaanalyisis of survival outcomes in first-line bevacizumab. Frühjahrstagung 2010 der ÖGHO, April 2010, Bregenz, Österreich - VORTRAG 34. BARTSCH R, DE VRIES C, ZIEBERMAYR R, BAGO-HORVATH Z, PLUSCHNIG U, DUBSKY P, GNANT M, ZIELINSKI CC, WELTERMANN A, STEGER GG. Fulvestrant (F) as first-line palliative treatment for ER-positive metastatic breast cancer (MBC) Annual Meeting of the American Society of Clinical Oncology, Juni 2010, Chicago, USA - POSTER Rupert Bartsch 12

13 35. BARTSCH R, DE VRIES C, FOEDERMAYR M, MADER RM, HUBER M, BAGO- HORVATH Z, PLUSCHNIG U, STEGER GG, DUBSKY P, FITZAL F, SCHREIL G, ZIELINSKI CC, GAMPENRIEDER P, ZIEBERMAYR R. Bevacizumab as first-line therapy for advanced breast cancer. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2010, Oktober 2010, Berlin, Deutschland - VORTRAG 36. BARTSCH R, BERGHOFF A, PLUSCHNIG U, BAGO-HORVATH Z, DUBSKY P, ROTTENFUSSER A, DE VRIES C, RUDAS M, FITZAL F, DIECKMANN K, GNANT M, ZIELINSKI CC, STEGER GG. Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from Her2-positive (Her2+) metastatic breast cancer (MBC) Annual Meeting of the American Society of Clinical Oncology, Juni 2011, Chicago, USA - POSTER 37. BARTSCH R, BERHOFF A, PLUSCHNIG U, BAGO-HORVATH Z, DUBSKY P, ROTTENFUSSER A, DE VRIES C, MADER R, ZIELINSKI CC, STEGER GG. Influence of systemic therapy on overall survival in patients with brain metastases from Her2-positive breast cancer. Frühjahrstagung 2011 der ÖGHO, Mai 2010, Pörtschach, Österreich - VORTRAG 38. BARTSCH R. VEGF-inhibition: Inconsistencies and failures in clinical trials. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2011, Oktober 2011, Basel, Schweiz VORTRAG (invited) 39. BARTSCH R, PREUSSER M, MAROSI C. Chemotherapy for brain metastases. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2011, Oktober 2011, Basel, Schweiz VORTRAG (invited) 40. BARTSCH R, BERGHOFF A, PLUSCHNIG U, BAGO-HORVATH Z, DUBSKY P, ROTTENFUSSER A, GNANT M, MADER R, ZIELINSKI CC, STEGER GG. Impact of systemic anti-her2 treatment on overall survival in patients with brain metastases from Her2- overexpressing breast cancer ECCO 16, September 2011, Stockholm, Schweden - POSTER 41. BERGHOFF A, BAGO-HORVATH Z, DUBSKY P, RUDAS M, PLUSCHNIG U, ROTTENFUSSER A, GNANT M, STEGER GG, ZIELINSKI CC, BARTSCH R. Brain metastases-free survival in patients with Her2-positive metastatic breast cancer ASCO Breast Cancer Symposium, September 2011, San Francisco, USA - POSTER 42. BARTSCH R, BERGHOFF A, BAGO-HORVATH Z, DEVRIES C, DUBSKY P, PLUSCHNIG U, RUDAS M, ROTTENFUSSER A, FITZAL F, DIECKMANN K, MADER RM, GNANT M, ZIELINSKI CC, STEGER GG. Brain metastasis free survival (BMFS) differs between breast cancer subtypes. 34 th Annual San Antonia Breast Cancer Symposium, Dezember 2011, San Antonio, Texas, USA POSTER 43. BARTSCH R, BAGO-HORVATH Z, PLUSCHNIG U, BERGHOFF A, DUBSKY P, MADER RM, FITZAL F, GNANT M, ZIELINSKI CC, STEGER GG. Ovarian function suppression plus fulvestrant in premenopausal women with metastatic breast cancer. Rupert Bartsch 13

14 Submitted to: The 8 th European Breast Cancer Conference (EBCC 8), März 2012, Wien, Österreich Coautor 1. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, ZIELINSKI CC, STEGER GG. Capecitabine-monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. ECCO 12, September 2003, Kopenhagen, Dänemark 2. MADER R, RIZOVSKI B, WENZEL C, BARTSCH R, ZIELINSKI CC, STEGER GG. Pharmacokinetics of epirubicin and paclitaxel during weekly administration in patients with metastasised breast cancer. ECCO 12, September 2003, Kopenhagen, Dänemark 3. WENZEL C, LOCKER GJ, BARTSCH R, PLUSCHNIG U, ZIELINSKI CC, STEGER GG. Capecitabine-monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Gemeinsame Jahrestagung der DGHO, ÖGHO und SGMO, Oktober 2003, Basel, Schweiz 4. STEGER GG, WENZEL C, BARTSCH R, RUDAS M, GNANT MF, ZIELINSKI CC, JAKESZ R. Preliminary results of a pilot-trial with trastuzumab and weekly epidoxorubicin / docetaxel in the neoadjuvant treatment of primary, operable breast cancer. Primary Therapy of Early Breast Cancer, 8 th International Conference, März 2003, St. Gallen, Schweiz 5. STEGER GG, BARTSCH R, WENZEL C, PLUSCHNIG U, LOCKER G, MADER RM, ZIELINSKI CC. Fulvestrant beyond the second hormonal treatment line in metastatic breast cancer Annual Meeting of the American Society of Clinical Oncology, Mai 2003 Chicago, USA 6. STEGER GG, BARTSCH R, WENZEL C, PLUSCHNIG U, LOCKER G, MADER RM, ZIELINSKI CC. Fulvestrant (Faslodex) demonstrates clinical benefit in heavily pre-treated patients with metastatic breast cancer. ECCO 12, September 2003, Kopenhagen, Dänemark 7. HUSSIAN D, WENZEL C, BARTSCH R, PLUSCHNIG U, ZIELINSKI CC, STEGER GG. Preoperative second-line chemotherapy induces objective responses in primary breast cancer. Gemeinsame Jahrestagung der DGHO, ÖGHO und SGMO, Oktober 2003, Basel, Schweiz 8. PLUSCHNIG U, HUSSIAN D, WENZEL C, BARTSCH R, ZIELINSKI CC, STEGER GG. Frequency of amenorrhea induced by adjuvant chemotherapy in premenopausal breast cancer patients induced by different chemotherapy regimen. New developments in breast cancer, November 2003, Monaco 9. STEGER GG, BARTSCH R, WENZEL C, PLUSCHNIG U, LOCKER G, MADER RM, ZIELINSKI CC. Fulvestrant (Faslodex) demonstrates clinical benefit in heavily pre-treated patients with metastatic breast cancer. Rupert Bartsch 14

15 26 th Annual San Antonia Breast Cancer Symposium, Dezember 2003, San Antonio, Texas, USA 10. WENZEL C, HUSSIAN D, BARTSCH R, PLUSCHNIG U, LOCKER GJ, GNANT M, JAKESZ R, ZIELINKSI CC, STEGER GG. Feasibility of Taxotere, Epirubicin and Xeloda (TEX) plus Pegfilgrastim as neoadjuvant treatment for primary breast cancer: a pilot study Annual meeting of the American Society of Clinical Oncology, Juni 2004, New Orleans, USA 11. STEGER GG, BARTSCH R, WENZEL C, HUSSIAN D, SEVELDA U, PLUSCHNIG U, MADER R, ZIELINSKI CC. Fulvestrant (FUL) and goserelin (GOS) in premenopausal women with advanced, hormone-sensitive breast cancer a pilot study Annual Meeting of the American Society of Clinical Oncology, Mai 2005, Orlando, USA 12. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, LOCKER GJ, SEVELDA U, ZIELINSKI CC, STEGER GG. Single administration of pegylated filgrastim once per cycle compared to daily filgrastim in patients with primary breast cancer receiving neoadjuvant chemotherapy Annual Meeting of the American Society of Clinical Oncology, Mai 2005, Orlando, USA 13. RADERER M, WOEHRER S, BARTSCH R, PRAGER G, DRACH J, HAJNA M, GAIGER A, TURETSCHEK K, JAEGER U, ZIELINSKI CC. A phase II study of oxaliplatin in patients with MALT-lymphoma Symposium on Leukaemia and Lymphoma, März 2005, Amsterdam, Niederlande 14. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, SEVELDA U, ZIELISNKI CC, STEGER GG. Pegyliertes Filgrastim (P) versus Filgrastim (F) zur Prävention von Chemotherapie-assoziierter Neutropenie bei Patientinnen mit primären Mammakarzinom. Gemeinsame Jahrestagung der Österreichischen, Deutschen und Schweizer Senologie Oktober 2005, Stuttgart, Deutschland 15. HUSSIAN D, WENZEL C, SEVELDA U, BARTSCH R, PLUSCHNIG U, MADER R, LOCKER G, GNANT M, JAKESZ R, ZIELISNKI CC, STEGER GG. Anaemia as prognostic factor in patients with primary breast cancer after neoadjuvant chemotherapy. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2005, Oktober 2005, Hannover, Deutschland 16. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, LOCKER G, SEVELDA U, ZIELISNKI CC, STEGER GG. Pegylated filgrastim (P) versus filgrastim (F) in primary prevention of chemotherapy associated neutropenia in the neoadjuvant treatment of primary breast cancer. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2005, Oktober 2005, Hannover, Deutschland 17. WENZEL C, HUSSIAN D, BARTSCH R, PLUSCHNIG U, SEVELDA U, LOCKER G, GNANT M, ZIELINSKI CC, JAKESZ R, STEGER GG. Invasive ductal carcinoma and invasive lobular carcinoma of the breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel+g-csf. Rupert Bartsch 15

16 ECCO 13, Oktober 2005, Paris, Frankreich 18. STEGER GG, BARTSCH R, WENZEL C, HUSSIAN D, SEVELDA U, PLUSCHNIG U, MADER R, ZIELINSKI CC. Results from a pilot study with goserelin plus fulvestrant in premenopausal women with advanced, hormone-sensitive breast cancer. ECCO 13, Oktober 2005, Paris, Frankreich 19. MADER R, FORSTNER B, BARTSCH R, WENZEL C, PLUSCHNIG U, ZIELINSKI C, STEGER G. Induction of thymidine phosphorylase by paclitaxel in patients with advanced breast cancer. Frühjahrstagung 2006 der ÖGHO, April 2006, Wels, Österreich 20. FROMM S, HOKE M, ROTTENFUSSER A, BARTSCH R, POTTER R, POKRAJAC B. A retrospective analysis of survival, local control and prognostic factors in node positive patients treated with adjuvant 3D-conformal radiotherapy. 10 th Central European Lung Cancer Conference, Juni 2006, Prag, Tschechien 21. ROTTENFUSSER A, GATTERBAUER B, LEHNERT M, BARTSCH R, FROMM S, MAROSI C, KITZ K, POETTER R, DIECKMANN K. Retrospective anlaysis of reirradiation in malignant glioma at the LNAC and gamma-knife: Experience at the Medical University of Vienna. Jahrestagung der EANO 2006, September 2006, Wien, Österreich 22. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, ALTORJAI G, GNANT M, ZIELINSKI C, JAKESZ R, STEGER G. Unterschiedliches Ansprechen zwischen invasiv duktalem und lobulärem Mammakarzinom auf präoperative Chemotherapie. Jahrestagung der österreichischen Gesellschaft für Senologie, September 2006, Salzburg, Österreich 23. STEGER GG, GREIL R, SAMONIGG H, JAKESZ R, BARTSCH R, MLINERITSCH B, MELBINGER-ZEINITZER E, MARTH C, SCHIPPINGER W, GNANT MF. An interim safety analysis of ABCSG-24: 6 cycles of docetaxel, epirubicin, and capecitabine + pegfilgrastim (DEC) vs. 6 cycles of docetaxel and epirubicin + pegfilgrastim (DE) in the neoadjuvant treatment of operable breast cancer. 29 th Annual San Antonia Breast Cancer Symposium, Dezember 2006, San Antonio, Texas, USA 24. ALTORJAI G, BARTSCH R, WENZEL C, PLUSCHNIG U, MADER RM, GNANT M, JAKESZ R, RUDAS M, ZIELINSKI CC, STEGER GG. Response to fulvestrant treatment is independent of Her2 receptor status. Frühjahrstagung 2007 der ÖGHO, April 2007, Wien, Österreich 25. STEGER GG, GREIL R, SAMONIGG H, JAKESZ R, BARTSCH R, MLINERITSCH B, MELBINGER-ZEINITZER E, MARTH C SCHIPPINGER W, GNANT MF, Austrian Breast and Colorectal Cancer study Group. Randomized comparison of neoadjuvant docetaxel (D), epirubicin (E) and pegfilgrastim (P) (+ trastuzumb [T] in Her2+ patients [pts]) with and without capecitabine (C) for operable breast cancer (BC): Results of a planned safety analysis of ABCSG Annual Meeting of the American Society of Clinical Oncology, Juni 2007, Chicago, USA Rupert Bartsch 16

17 26. FROMM S, HOKE M, ROTTENFUSSER A, BARTSCH R, POTTER R, POKRAJAC B. A retrospective analysis of survival, local control and prognostic factors in node positive nonsmall cell lung cancer patients treated with adjuvant 3D-conformal radiotherapy. Jahrestagung der Deutschen Gesellschaft für Radioonkologie 2007, Juni 2007, Hannover, Deutschland 27. ALTORJAI G, BARTSCH R, ROTTENFUSSER A, WENZEL C, DIECKMANN K, PLUSCHNIG U, RUDAS M, MADER RM, POETTER R, ZIELINSKI CC, STEGER GG. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2007, Oktober 2007, Basel, Schweiz 28. ROTTENFUSSER A, GATTERBAUER B, BARTSCH R, MAROSI C, KITZ K, PÖTTER R, DIECKMANN K. Retrospektive Analyse der Re-irradiatio von Gliomen mittels Gamma-knife und LINAC: Erfahrungen an der Medizinischen Universität Wien. Aktualisierte Daten. Jahrestagung der Österreichischen Gesellschaft für Radioonkologie 2007, Oktober 2007, Graz, Österreich 29. KNAUER M, ROTTENFUSSER A, BARTSCH R, DIECKMANN K, WENZEL C, FROMM S, EITER G, STEGER GG, ZIELINSKI CC, DE VRIES A. Analysis of risk factors predicting time to development of brain metastases Annual Meeting of the American Society of Clinical Oncology, Juni 2008, Chicago, USA 30. ROTTENFUSSER A, LÜTGENDORF-CAUCIG C, ALTORJAI G STOCK M, WINKLER P, KROUPA B, BARTSCH R, GEORG D, PÖTTER R; DIECKMANN K. Stereotaktische Radiotherapie (SRT) zur Behandlung von Hepatozellulären Carcinomen (HCC) - Erfahrungen an der Medizinischen Universität Wien. Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaften für Radioonkologie 2008, Mai 2008, Wien, Österreich 31. ROTTENFUSSER A, KNAUER M, FROMM S, BARTSCH R, EITER H, ALTORJAI G, LÜTGENDORF-CAUCIG C, WENZEL C, PÖTTER R, DE VRIES A; DIECKMANN K. Early development of brain metastases from breast cancer: Analysis of potential risk factors. Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaften für Radioonkologie 2008, Mai 2008, Wien, Österreich 32. DIECKMANN K, ROTTENFUSSER A, PREUSSER M, HASSLER M, BARTSCH R, LÜTGENDORF-CAUCIG C, ALTORJAI G, MAROSI C, PÖTTER R. Ergebnisse von 447 kombiniert operativ und radio-chemotherapeutisch behandelten Patienten mit Glioblastom an der Medizinischen Universität Wien. Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaften für Radioonkologie 2008, Mai 2008, Wien, Österreich 33. STEGER GG, MLINERITSCH B, BARTSCH R, GNANT M, NIERNBERGER T, PLUSCHNIG U, GREIL R, POBER M, SEVELDA P, THALER J, ZIELINSKI CC, on behalf of the Austrian Fulvestrant Registry. Results from the Austrian Fulvestrant Registry. Frühjahrstagung 2008 der ÖGHO, April 2008, Innsbruck, Österreich Rupert Bartsch 17

18 34. ROTTENFUSSER A, PREUSSER M, ALTORJAI G, BARTSCH R, LÜTGENDORF- CAUZCIG C, HASSLER M, CZECH T, HAINFELLNER J, MAROSI C, POETTER R, DIECKMANN K. Results from 447 patients treated with combined modality therapy for glioblastoma multiforme (GBM) at the Medical University of Vienna Annual Meeting of the European Society of Therapeutic Radiology and Oncology, September 2008, Göteborg, Schweden 35. GAMPENRIEDER SP, BARTSCH R, PLUSCHNIG U, SCHEUER R, MATZNELLER P, DUBSKY P, GNANT M, ZIELISNKICC, STEGER GG. An all-oral chemotherapy in locally advanced and metastatic breast cancer. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2008, Oktober 2008, Wien, Österreich 36. DIECKMANN K, PREUSSER M, ROTTENFUSSER A, BARTSCH R, HASSLER M, CZECH T, HAINFELLBER J, POETTER P, MAROSI C. Combined-modality Therapy for Glioblastoma Multiforme at the University of Vienna Austria: Results from 448 Patients Annual Meeting of the American Society of Therapeutic Radiology and Oncology, September Juni 2008, Boston, USA 37. WILTSCKE C, WIEDERMANN U, BARTSCH R, ZURBRIGGEN R, BRÄMSWIG K, STEGER GG, JASINSKA J, SCHEINER O, PEHAMBERGER H, ZIELINSKI CC. A HER2 multi-peptide virosome vaccine induced HER-2 specific antibodies in patients with metastatic breast cancer: final results of a phase I study to evaluate safety and immunogenicity Annual Meeting of the American Association of Cancer Research, April 2009, Denver, USA 38. PLUSCHNIG U, HASLIK W, BARTSCH R, SOLEIMAN A, WENZEL W, STEGER GG, ZIELINSKI C, MADER RM. Das Auftreten von zwei unabhängigen Anthrazyklinparavasaten bei einer Patientin mit Mammakarzinom: Ein Fallbericht. Jahrestagung der österreichischen Gesellschaft für Senologie, September 2009, Velden, Österreich 39. KIERNER K, GARTNER V, BARTSCH R, WATZKE H. Zuweisungsverhalten österreichischer OnkologInnen zu palliativmedizinischen Einrichtungen. 40. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin, September 2009, Wien, Österreich 40. PLUSCHNIG U, ZACHERL J, SCHOPPMANN S, RADERER M, PRAGER G, BARTSCH R, BA-SSALAMAH A, ZIELINSKI CC, HEJNA M. Neoadjuvante Therapie des primär operablen Magenkarzinoms mit Epirubicin / Oxaliplatin / Capecitabine (EOX). 26. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO- ASSO), Oktober 2009, St. Wolfgang, Österreich 41. FTZAL F, MITTLBOECK M, RIEDL O, BLAHA P, STEGER G, BARTSCH R, DUBSKY P, JAKESZ R, GNANT M. Breast conserving therapy after neoadjuvant treatment: is it safe? 26. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO- ASSO), Oktober 2009, St. Wolfgang, Österreich Rupert Bartsch 18

19 42. RIEDL O, MITTLBOECK M, STEGER G, BARTSCH R, RUDAS M, OLUSCHNIG U, JAKESZ R, GNANT M, FIRTAL F. Inclusion criteria for the use of neoadjuvant chemotherapy in breast cancer. 26. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO- ASSO), Oktober 2009, St. Wolfgang, Österreich 43. RIEDL O, MITTLBOECK M, STEGER G, BARTSCH R, RUDAS M, DUBKSY P, JAKESZ R, GNANT M, FITZAL F. Inclusion criteria for the use of neoadjuvant chemotherapy in breast cancer. The 7 th European Breast Cancer Conference (EBCC 7), März 2010, Barcelona, Spanien 44. FITZAL F, MITTLBOECK M, RIEDL O, BLAHA P, DUBSKY P, STEGER G, BARTSCH R, JAKESZ R, GNANT M. Breast conserving therapy after neoadjuvant treatment: Is it oncologic safe? The 7 th European Breast Cancer Conference (EBCC 7), März 2010, Barcelona, Spanien 45. RO J, MYUNG SK, BERTON-RIGAUD D, BARTSCH R, GNANT M, STEGER GG. The addition of capecitabine to neoadjuvant chemotherapy for early breast cancer (EBC): a review of clinical study data. The 7 th European Breast Cancer Conference (EBCC 7), März 2010, Barcelona, Spanien 46. PLUSCHNIG U, ZACHERL J, SCHOPPMANN S, RADERER M, PRAGER G, BARTSCH R, BA-SSALAMAH A, LAMM W, ZIELINSKI CC, HEJNA M. Neoadjuvant chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX) for resectable gastric cancer: A single institution experience Annual Meeting of the American Society of Clinical Oncology, Juni 2010, Chicago, USA 47. MADER RM, BARTSCH R, FORSTNER B, KALIPCIYAN M, STEGER GG. Efficacy of epirubicin and docetaxel in Her2-overexpressing breast cancer cell lines. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2010, Oktober 2010, Berlin, Deutschland 48. STEGER GG, MLINERITSCH B, BARTSCH R, PLUSCHNIG U, PETRU E, PEINTINGER F, SEVELDA P, GREIL R. Non-pegylated liposomal doxorubicin in metastatic breast cancer (MBC) Results from an Austrian post marketing surveillance programme. Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2010, Oktober 2010, Berlin, Deutschland 49. FITZAL F, MITTLBOECK M, STEGER G, BARTSCH R, RUDAS M, DUBSKY P, RIEDL O, JAKESZ R, GNANT M. Neoadjuvant chemotherapy should also be considered for lobular breast cancer. St. Gallen Oncology Primary Therapy for Early Breast Cancer 2011, März 2011, St. Gallen, Schweiz 50. PLUSCHNIG U, ZACHERL J, SCHOPPMANN S, RADERER M, PRAGER G, BARTSCH R, BA-SSALAMAH A, LAMM W, ZIELINSKI C, HEJNA M. Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX) ASCO Gastrointestinal Cancers Symposium, Jänner 2011, San Francisco, USA Rupert Bartsch 19

20 51. KNAUER M, BACHLEITNER-HOFMANN T, BARTSCH R, HAID A, WENZL E, TABERNO J, ROSENBERG R, LUTKE-HOLZIK M, BIBEAU F, VAN DER HOEVEN JJM, SALAZAR R. Gene expression profiling in colon cancer: improvement of recurrence risk assessment. 52. Österreichischer Chirurgenkongress, Juni 2011, Wien, Österreich 52. BERGHOFF A, BARTSCH R, BAGO-HORVATH Z, DUBSKY P, RUDAS M, PLUSCHNIG U, WILTSCHKE C, GNANT M, STEGER GG, ZIELINSKI CC. Impact of Her2-targeted therapy on overall survival (OS) in patients (pts) with Her2-positive (Her2+) metastatic breast cancer (MBC) 2011 Annual Meeting of the American Society of Clinical Oncology, Juni 2011, Chicago, USA 53. BERGHOFF A, BARTSCH R, BAGO-HORVATH Z, DUBSKY P, RUDAS M, PLUSCHNIG U, WILTSCHKE C, GNANT M, STEGER GG, ZIELINSKI CC. Impact of Trastuzumab (T) beyond disease progression on overall survival (OS): a retrospective singlecenter analysis. Frühjahrstagung 2011 der ÖGHO, Mai 2010, Pörtschach, Österreich 54. PETRICEVIC B, LÄNGLE J, SINGER J, STEGER G, BARTSCH R, JENSEN- JAROLIM E, BERGMANN M. Die Verwendung eines FACS-basierten Assays zur Evaluierung der Trastuzumab-assoziierten Antikörper-vermittelte zelluläre Zytotoxizität bei Patientinnen mit metastasiertem HER2/neu positiven Brustkrebs. 28. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO- ASSO), Oktober 2011, St. Wolfgang, Österreich Rupert Bartsch 20